RT Journal Article
T1 Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.
A1 Jiménez-Fonseca, Paula
A1 Carmona-Bayonas, Alberto
A1 Sánchez Lorenzo, Maria Luisa
A1 Plazas, Javier Gallego
A1 Custodio, Ana
A1 Hernández, Raquel
A1 Garrido, Marcelo
A1 García, Teresa
A1 Echavarría, Isabel
A1 Cano, Juana María
A1 Rodríguez Palomo, Alberto
A1 Mangas, Monserrat
A1 Macías Declara, Ismael
A1 Ramchandani, Avinash
A1 Visa, Laura
A1 Viudez, Antonio
A1 Buxó, Elvira
A1 Díaz-Serrano, Asunción
A1 López, Carlos
A1 Azkarate, Aitor
A1 Longo, Federico
A1 Castañón, Eduardo
A1 Sánchez Bayona, Rodrigo
A1 Pimentel, Paola
A1 Limón, Maria Luisa
A1 Cerdá, Paula
A1 Álvarez Llosa, Renata
A1 Serrano, Raquel
A1 Lobera, Maria Pilar Felices
A1 Alsina, María
A1 Hurtado Nuño, Alicia
A1 Gómez-Martin, Carlos
K1 Gastric cancer
K1 HER2 testing
K1 Personalized medicine
K1 Quality of care
K1 Trastuzumab
AB Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of HER2 testing on patient prognosis in a national registry of AGC. This Spanish National Cancer Registry includes cases who were consecutively recruited at 28 centers from January 2008 to January 2016. The effect of missing HER2 status was assessed using stratified Cox proportional hazards (PH) regression. The rate of HER2 testing increased steadily over time, from 58.3 % in 2008 to 92.9 % in 2016. HER2 was positive in 194 tumors (21.3 %). In the stratified Cox PH regression, each 1 % increase in patients who were not tested for HER2 at the institutions was associated with an approximately 0.3 % increase in the risk of death: hazard ratio, 1.0035 (CI 95 %, 1.001-1.005), P = 0.0019. Median OS was significantly lower at institutions with the highest proportions of patients who were not tested for HER2. Patients treated at centers that took longer to implement HER2 testing exhibited worse clinical outcomes. The speed of implementation behaves as a quality-of-care indicator. Reviewed guidelines on HER2 testing should be used to achieve this goal in a timely manner.
YR 2016
FD 2016-09-06
LK http://hdl.handle.net/10668/10422
UL http://hdl.handle.net/10668/10422
LA en
DS RISalud
RD May 31, 2025